Sign Up for Email Alerts
Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
  • Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
  • Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
  • Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
  • Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
Post placeholder image
May 13, 2020 in Biotech Industry News

Seattle Biotech CEO Keeps A Watchful Eye on the Market for Potential IPO

Kineta Inc 8 Like Post Comments Off on Seattle Biotech CEO Keeps A Watchful Eye on the Market for Potential IPO
Read More

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • About Us
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2025 Kineta Inc.        Privacy Policy       Terms of Use

English
English
Korean